<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS94260</article-id>
<article-id pub-id-type="doi">10.1101/2020.08.25.256339</article-id>
<article-id pub-id-type="archive">PPR205935</article-id>
<article-version article-version-type="publisher-id">3</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Walser</surname>
<given-names>Marcel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Rothenberger</surname>
<given-names>Sylvia</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Hurdiss</surname>
<given-names>Daniel L.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schlegel</surname>
<given-names>Anja</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Calabro</surname>
<given-names>Valérie</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fontaine</surname>
<given-names>Simon</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Villemagne</surname>
<given-names>Denis</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paladino</surname>
<given-names>Maria</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hospodarsch</surname>
<given-names>Tanja</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Neculcea</surname>
<given-names>Alexandra</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cornelius</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schildknecht</surname>
<given-names>Patricia</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matzner</surname>
<given-names>Mirela</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hänggi</surname>
<given-names>Martin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Franchini</surname>
<given-names>Marco</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kaufmann</surname>
<given-names>Yvonne</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schaible</surname>
<given-names>Doris</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schlegel</surname>
<given-names>Iris</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iss</surname>
<given-names>Chloe</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Looser</surname>
<given-names>Thamar</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mangold</surname>
<given-names>Susanne</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herzog</surname>
<given-names>Christel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schiegg</surname>
<given-names>Dieter</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reichen</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Radom</surname>
<given-names>Filip</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bosshart</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lehmann</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haeuptle</surname>
<given-names>Micha A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zürcher</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vagt</surname>
<given-names>Toni</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sigrist</surname>
<given-names>Gabriel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Straumann</surname>
<given-names>Marcel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Proba</surname>
<given-names>Karl</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veitonmäki</surname>
<given-names>Niina</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dawson</surname>
<given-names>Keith M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zitt</surname>
<given-names>Christof</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mayor</surname>
<given-names>Jennifer</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ryter</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lyoo</surname>
<given-names>Heyrhyoung</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chunyan</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Wentao</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Drulyte</surname>
<given-names>Ieva</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Du</surname>
<given-names>Wenjuan</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Binz</surname>
<given-names>H. Kaspar</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Waal</surname>
<given-names>Leon</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stittelaar</surname>
<given-names>Koert J.</given-names>
</name>
<xref ref-type="aff" rid="A9">8*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taplin</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="A10">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lewis</surname>
<given-names>Seth</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Steiner</surname>
<given-names>Daniel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Kuppeveld</surname>
<given-names>Frank J.M.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Engler</surname>
<given-names>Olivier</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Bosch</surname>
<given-names>Berend-Jan</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Stumpp</surname>
<given-names>Michael T.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">10</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Amstutz</surname>
<given-names>Patrick</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Molecular Partners AG, Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland</aff>
<aff id="A2">
<label>2</label>Spiez Laboratory, Austrasse, 3700 Spiez, Switzerland</aff>
<aff id="A3">
<label>3</label>Institute of Microbiology, University Hospital Center and University of Lausanne, Rue du Bugnon 48, 1011 Lausanne, Switzerland</aff>
<aff id="A4">
<label>4</label>Department Biomolecular Health Sciences, Division Infectious Diseases &amp; Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, 3584 CL, Utrecht, The Netherlands</aff>
<aff id="A5">
<label>5</label>Cryo-Electron Microscopy, Bijvoet Center for Biomolecular Research, Department of Chemistry, Faculty of Science, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands</aff>
<aff id="A6">
<label>6</label>Materials and Structural Analysis, Thermo Fisher Scientific, Eindhoven, 5651 GG, The Netherlands</aff>
<aff id="A7">
<label>7</label>Binz Biotech Consulting, Lüssirainstrasse 52, 6300 Zug</aff>
<aff id="A8">
<label>8</label>Viroclinics Xplore, Landerd Campus, Nistelrooise Baan 3, 5374 RE, Schaijk, The Netherlands</aff>
<aff id="A9">
<label>8*</label>Wageningen Bioveterinary Research, PO Box 65, 8200 AB, Lelystad, the Netherlands</aff>
<aff id="A10">
<label>9</label>Integrated Biologix GmbH, Steinenvorstadt, 33, Basel, CH-4051, Switzerland</aff>
<author-notes>
<corresp id="CR1">
<label>10</label>To whom correspondence should be addressed: Michael T. Stumpp; +41 44 755 77 00; <email>info@molecularpartners.com</email>
</corresp>
<fn id="FN1">
<p id="P1">Summarizing 125-character sentence: <bold>Generation of ensovibep, the first clinical-stage trivalent anti-SARS-CoV-2 therapeutic candidate.</bold>
</p>
</fn>
<fn id="FN2">
<p id="P2">DARPin<sup>®</sup> is a registered trademark owned by Molecular Partners AG</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>26</day>
<month>08</month>
<year>2020</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P3">Globally accessible therapeutics against SARS-CoV-2 are urgently needed. Here, we report the generation of the first anti-SARS-CoV-2 DARPin molecules with therapeutic potential as well as rapid large-scale production capabilities. Highly potent multivalent DARPin molecules with low picomolar virus neutralization efficacies were generated by molecular linkage of three different monovalent DARPin molecules. These multivalent DARPin molecules target various domains of the SARS-CoV-2 spike protein, thereby limiting possible viral escape. Cryo-EM analysis of individual monovalent DARPin molecules provided structural explanations for the mode of action. Analysis of the protective efficacy of one multivalent DARPin molecule in a hamster SARS-CoV-2 infection model demonstrated a significant reduction of pathogenesis. Taken together, the multivalent DARPin molecules reported here, one of which has entered clinical studies, constitute promising therapeutics against the COVID-19 pandemic.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>COVID-19</kwd>
<kwd>corona virus</kwd>
<kwd>antiviral therapy</kwd>
<kwd>post-exposure prophylaxis</kwd>
<kwd>DARPin<sup>®</sup> drug</kwd>
<kwd>ankyrin repeat protein</kwd>
<kwd>multispecific</kwd>
<kwd>ribosome display</kwd>
<kwd>ensovibep</kwd>
<kwd>MP0420</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P4">Fighting the COVID-19 pandemic will require coordinated global efforts to maximize the benefits of vaccinations and therapeutics(<xref ref-type="bibr" rid="R1">1</xref>). Even though vaccine and therapeutic development efforts have progressed considerably, there is, and will be, a remaining medical need for globally accessible therapeutics to treat patients and to protect health care workers, as well as individuals with underlying medical conditions that preclude them from being vaccinated. Neutralizing monoclonal antibodies are expected to be critically important and could be readily available(<xref ref-type="bibr" rid="R2">2</xref>–<xref ref-type="bibr" rid="R4">4</xref>), however they are complex to manufacture and come at a considerable cost. These logistical hurdles may severely limit accessibility, thus preventing an effective global solution(<xref ref-type="bibr" rid="R5">5</xref>).</p>
<p id="P5">DARPin molecules are an emerging class of novel therapeutics that are actively being developed in ophthalmology and oncology, with four molecules at a clinical stage(<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>). Here, we report the generation and characterization of the first anti-viral DARPin molecules in the context of the COVID-19 pandemic. DARPin molecules are based on naturally occurring ankyrin repeat motifs. To generate therapeutic DARPin molecules, a pure <italic>in vitro</italic> approach (i.e. selections via ribosome display) is possible and can be carried out in a very short time frame, only requiring the target protein, in this case the SARS-CoV-2 spike protein or subdomains thereof. Hence, therapeutic DARPin molecules can be prepared independently of patient samples or animal immunizations. DARPin molecules can be monovalent and thus monospecific or linked by peptide linkers to form single-chain multivalent or multispecific DARPin molecules with several specificities. Notably, DARPin molecules can be manufactured by microbial fermentation, and thus be potentially available world-wide within a short time due to lower technical requirements to provide large-scale clinical grade material. Additionally, the high heat stability of DARPin molecules offers the prospect of a reduced cold chain for distribution around the globe.</p>
<p id="P6">The SARS-CoV-2 spike protein(<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R9">9</xref>), presented as a metastable prefusion trimer at the viral surface, mediates virus entry into the host cell. The spike protein comprises multiple functional domains: S1, which includes the N-terminal domain (NTD) and the receptor binding domain (RBD) responsible for interaction with the angiotensin-converting enzyme 2 (ACE2) host receptor(<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R11">11</xref>), and the S2 domain, which is responsible for virus-host cell membrane fusion via extensive, irreversible conformational changes(<xref ref-type="bibr" rid="R12">12</xref>–<xref ref-type="bibr" rid="R14">14</xref>). This domain composition opens the possibility to target several sites on a single viral protein, leading to multiple mechanisms of inhibition. Such a multi-pronged approach is expected to lead to higher potencies, lower doses, and better protection against potential viral escape mutations.</p>
<p id="P7">Here, we present a novel approach using DARPin molecules to simultaneously bind three sites on the trimeric SARS-CoV-2 spike protein. The results reported below describe the development and characterization of monospecific DARPin molecules against distinct domains of the spike protein, the selection process for the most potent monospecific DARPin molecules and, supported by cryo-EM data, their rational combination into highly potent multivalent as well as multispecific DARPin molecules. Furthermore, we demonstrate the protective efficacy of a multivalent DARPin molecule against virus replication and severe disease in a hamster model of COVID-19. We anticipate that antiviral multivalent DARPin molecules have the potential to become an easy-to-deploy antiviral approach for treatment and/or prevention of COVID-19. Based on the results presented here, MP0420 or ensovibep - a multispecific RBD-binding DARPin candidate, is currently being studied in Phase 2 clinical trials.</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<sec id="S3">
<title>Selection and characterization of monovalent DARPin molecules targeting different regions of the SARS-CoV-2 spike protein</title>
<p id="P8">The DARPin technology is based on naïve DARPin libraries(<xref ref-type="bibr" rid="R6">6</xref>), with a physical diversity of about 10<sup>12</sup> different monovalent DARPin molecules, allowing the selection of sets of very diverse binding molecules by ribosome display(<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R16">16</xref>), the method of choice when dealing with libraries of such large diversities. DARPin libraries are based on a consensus design approach using hundreds of ankyrin repeat protein sequences of the human and mouse genome(<xref ref-type="bibr" rid="R17">17</xref>). An overview of the entire generation process of anti-SARS-CoV-2 spike protein binding DARPin molecules is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. To obtain individual DARPin molecules binding to distinct domains of the SARS-CoV-2 spike protein and potentially inhibiting viral cell entry, we focused on generating DARPin molecules binding to the receptor binding domain (RBD), the S1 N-terminal domain (NTD) or the S2 domain(<xref ref-type="bibr" rid="R18">18</xref>). After four ribosome display selection rounds (<xref ref-type="fig" rid="F1">Figure 1A</xref>), we further enriched for the most potently binding DARPin molecules through screening of 3’420 <italic>E. coli</italic> cell extracts overexpressing individual DARPin molecules by homogeneous time-resolved fluorescence (HTRF) assays for binding to different spike protein domains (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Based on binding and ACE2 inhibition profiles obtained in HTRF, which allowed mapping of monovalent DARPin molecules to different spike domains, 380 DARPin molecules were selected to be expressed in 96-well format and purified to homogeneity. DARPin molecules were further characterized for antiviral potency in a VSV-pseudovirion neutralization assay (PsV NA) as well as biophysically by size exclusion chromatography (SEC), Sypro-Orange thermal stability assessment(<xref ref-type="bibr" rid="R19">19</xref>), ProteOn surface plasmon resonance (SPR) target affinity assessment, and ELISA, to orthogonally evaluate target binding (<xref ref-type="fig" rid="F1">Figure 1C and D</xref>). In parallel to the characterization of the 380 monovalent DARPin molecules, 6 monovalent DARPin molecules of known spike domain specificity were used to randomly assemble a set of 192 tri-specific DARPin molecules (<xref ref-type="fig" rid="F1">Figure 1E</xref>). The antiviral potencies, determined in a PsV-NA screening assay, of these randomly combined tri-specific DARPin molecules provided valuable information on the most potent tri-specific combinations and formats. Based on the combined data for the 380 monovalent DARPin molecules, 11 of them with low pM to low nM affinities, excellent biophysical properties, diversities in amino acid sequences as well as binding for various SARS-CoV-2 spike protein domains (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>) were selected for the rational generation of 22 multivalent DARPin molecules described below (<xref ref-type="fig" rid="F1">Figure 1F</xref>). After detailed characterization of these 22 multivalent DARPin candidates, systemic exposure was assessed in mice and in Syrian golden hamsters for the most promising multivalent DARPin candidates (<xref ref-type="fig" rid="F1">Figure 1G</xref>). The multivalent DARPin candidate with the longer systemic half-life was evaluated for SARS-CoV-2 protection in a Covid-19 Syrian golden hamster model (<xref ref-type="fig" rid="F1">Figure 1H</xref>).</p>
</sec>
<sec id="S4">
<title>Rational design of multivalent DARPin molecules targeting the SARS-CoV-2 spike protein</title>
<p id="P9">We aimed to increase virus neutralizing potency through molecular linkage of monovalent DARPin molecules leading to avidity effects. Using the 11 selected mono-specific DARPin molecules, a total of 22 multivalent DARPin molecules were generated and characterized in detail, each comprising 3 monovalent DARPin molecules against various epitopes of the spike protein as well as two monovalent DARPin molecules binding to human serum albumin (HSA), which have been previously shown to confer long half-life to other DARPin molecules in animals and humans(<xref ref-type="bibr" rid="R7">7</xref>) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>). Each of the 22 multivalent DARPin molecules contained at least one RBD-binding domain since preventing ACE2 receptor interaction is assumed to be the strongest point of interference with virus entering the host cell. Multivalent DARPin molecules were designed to contain several binding modules to RBD (multi-RBD DARPin molecules) or to several distinct domains (multi-mode DARPin molecules). Based on profiling of 22 multivalent DARPin molecules for their biophysical properties and antiviral potency (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>), we selected two multivalent DARPin molecules, representative for the two different design strategies (i.e. Multi-RBD-DARPin-Candidate, MR-DC, and Multi-Mode-DARPin-Candidate, MM-DC) for further analysis (<xref ref-type="fig" rid="F2">Figure 2b</xref>). DNA sequencing of the individual monovalent DARPin components of MR-DC revealed a similar, but not identical, arrangement of amino acids, suggesting that they share a common mechanism of binding to the RBD. In contrast, the individual components of MM-DC exhibited a high level of sequence diversity, consistent with their different targeting mechanisms (<xref ref-type="fig" rid="F2">Figure 2c</xref>). Neutralization potency for MR-DC and MM-DC was 56 and 36-fold higher in PsV NA, respectively, relative to the most potent neutralizing individual monovalent DARPin that was used for the design of the two types of multivalent DARPin molecules (<xref ref-type="fig" rid="F2">Figure 2d-e</xref>). In addition, IC<sub>50</sub> values for potency determination in a VSV-SARS-CoV2 pseudotype neutralization assay for MR-DC and MM-DC was similar or superior to that of three earlier described potent neutralizing antibodies(<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R21">21</xref>). Neutralization assays with the infectious SARS-CoV-2 yielded IC<sub>50</sub> values of 12 pM for MR-DC (1 ng/ml) and 80 pM for MM-DC (7 ng/ml), respectively (<xref ref-type="fig" rid="F2">Figure 2f</xref>). Still, despite slightly higher potencies displayed by some other screened multi-valent DARPin candidates (e.g. M6, M7, M20 and M22), candidates MR-DC and MM-DC were selected as lead candidates to provide the highest diversity within their paratopes, and potentially the best possible protection against viral escape mutations. In addition, both multivalent DARPin molecules could effectively neutralize pseudotype viruses carrying spike proteins containing natural occurring polymorphisms, including the frequently occurring D614G mutation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>). The extremely high neutralization potencies are key for SARS-CoV-2 treatment in particular in a prophylactic setting where very low virus titers at the beginning of the infection are expected.</p>
</sec>
<sec id="S5">
<title>Cryo-EM analysis of monovalent DARPin molecules</title>
<p id="P10">To gain further insights into the mode of inhibition and binding, three individual monovalent DARPin molecules targeting RBD, S1-NTD, or S2, were subjected to cryo-electron microscopy (cryo-EM) analysis in complex with the trimeric spike ectodomain. In each case, few intact spikes remained following incubation with the monovalent DARPin molecules, particularly with the S2 binder (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2</xref>). When spike ectodomains were incubated with RBD-binding monovalent DARPin molecule #3 for 15 seconds prior to vitrification, 3D classification revealed that 65% of the intact S ectodomains were in the closed conformation, 20% had two RBDs in the open conformation and 15% had all three RBDs in the open conformation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3a</xref>). For the open RBD classes, additional density, consistent with the size of a monovalent DARPin molecule, was present on the RBD receptor binding ridge (RBR). When the incubation time was increased to 60 seconds, 66% of S ectodomains had three monovalent DARPin-bound RBDs in the open conformation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3b</xref>). Interestingly, 18% of the S ectodomains had two DARPin-bound RBDs in the open conformation and one trapped in a partially-closed conformation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figures 3b and 4</xref>). These results demonstrate that monovalent DARPin #3 binding prevents closure of the RBD through a previously described ratcheting mechanism(<xref ref-type="bibr" rid="R18">18</xref>). 3D refinement of the fully open class, from the 60 second incubated sample, produced a 4.2 Å global resolution map (<xref ref-type="fig" rid="F3">Figure 3a</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3c-e</xref>). The resolution of the map was sufficient to unambiguously assign the pose of RBD-binding monovalent DARPin molecule #3, which binds perpendicular to the RBD receptor binding motif (RBM), with its N-terminus orientated toward the spike three-fold symmetry axis (<xref ref-type="fig" rid="F3">Figure 3a</xref>). The concave DARPin binding surface covers the RBR and overlaps with the ACE2 binding site (<xref ref-type="fig" rid="F3">Figure 3b</xref>). Based on the cryo-EM data, molecular docking experiments were performed. The top scoring model indicated that the interface area is ~700 Å<sup>
<xref ref-type="bibr" rid="R2">2</xref>
</sup> and that key epitope residues are F456, Y473, F486, N487 and Y489, which putatively form an interface of hydrophobic interactions and hydrogen-bonds with the DARPin molecule #3 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 5</xref>). Taken together, these data show that RBD-binding monovalent DARPin molecule #3 inhibits SARS-CoV-2 through receptor functional mimicry, facilitating fusogenic conformational rearrangements of the spike protein. This mechanism of inhibition was also observed for a SARS-CoV neutralizing antibody, S230(<xref ref-type="bibr" rid="R18">18</xref>), and more recently for a SARS-CoV-2 neutralizing antibody, C105(<xref ref-type="bibr" rid="R22">22</xref>). Based on our cryo-EM structure, molecular modelling was used to demonstrate that a linker, used in the multivalent DARPin format, would permit simultaneous binding of three RBD-targeting monovalent DARPin molecules (<xref ref-type="fig" rid="F3">Figure 3c</xref>).</p>
<p id="P11">Following a 15 second incubation with the S1-NTD-binding monovalent DARPin molecule #9, 2D classification already revealed clear additional density bound to the spike NTD (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2</xref>). Subsequent 3D classification revealed that most of the DARPin-bound spikes were in the closed conformation, and 19% had one RBD in open conformation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 6a</xref>). 3D refinement of the fully closed class produced an 8 Å global resolution map (<xref ref-type="fig" rid="F3">Figure 3d</xref> and <xref ref-type="supplementary-material" rid="SD1">supplementary Figure 6b-c</xref>), sufficient to dock and assign the pose of the bound DARPin molecule (<xref ref-type="fig" rid="F3">Figure 3d</xref>). This monovalent DARPin molecule binds to the most distal region of the NTD, which is not resolved in the majority of available spike structures(<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R23">23</xref>). However, several spike structures with nearly completely modelled NTDs were recently reported(<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R25">25</xref>). The better resolved NTD loops in these structures allowed us to further narrow down the DARPin epitope, indicating that the concave binding surface is ideally situated to interact with the N5 loop, encompassing residues 246-258(<xref ref-type="bibr" rid="R26">26</xref>) (<xref ref-type="fig" rid="F3">Figure 3e</xref>). A recently described monoclonal antibody, 4A8(<xref ref-type="bibr" rid="R26">26</xref>), also targets the NTD, involving an extensive hydrophilic interaction network with the N3 loop and, to a lesser extent, the N5 loop. In contrast, molecular docking experiments suggest monovalent DARPin molecule #9 interacts with the NTD primarily with N5 loop residues 248-252 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 7</xref>), with an interface area of ~600 Å<sup>
<xref ref-type="bibr" rid="R2">2</xref>
</sup> and involving both hydrophilic and hydrophobic interactions. Based on our cryo-EM structures, molecular modelling was used to demonstrate that a linker, used in the multivalent DARPin format, would permit simultaneous binding of the NTD and RBD-targeting monovalent DARPin molecules (<xref ref-type="fig" rid="F3">Figure 3f</xref>).</p>
<p id="P12">Cumulatively, our structural analysis allowed us to generate models of the MR-DC and MM-DC molecules in contact with the spike protein using 3D molecular modeling tools (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 8</xref>). In both cases, the half-life extension modules have sufficient space to bind HSA. Within the distance limited by the linker length, we identified a potential binding site for the S2 binder, suggesting that simultaneous binding to the spike protein is feasible. However, structural analysis of S ectodomains incubated with the S2 binder #10 did not reveal any unambiguous density for the bound monovalent DARPin. The low number of intact ectodomains remaining after incubation with monovalent DARPin #10 suggests that, compared to monovalent DARPin molecules #3 and #9, the S2 binder has the greatest destabilizing effect on the structural integrity of the S ectodomains (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2</xref>).</p>
</sec>
<sec id="S6">
<title>In vivo antiviral efficacy of a multivalent DARPin in a SARS-CoV-2 hamster infection model</title>
<p id="P13">In order to assess the <italic>in vivo</italic> antiviral efficacy of our multivalent DARPin molecule MR-DC, a hamster Covid-19 disease model was performed to study the potential for preventing SARS-CoV-2 related disease (<xref ref-type="fig" rid="F4">Figure 4a</xref>). Syrian golden hamsters (6 females per group) were treated with a single intraperitoneal dose of one multivalent DARPin molecule, MR-DC, using either 16 μg, 160 μg, 1600 μg (per animal; average body weight of ~160g), or with placebo, 24 h prior to intranasal infection with SARS-CoV-2. Readouts included observation of macroscopic assessment of tissues, histopathology, body weight and virus titers. Dose-dependent reduction in tissue damage, immune response to infection, body weight loss, virus titers in throat, nasal turbinates and lung tissue was observed, indicating significant anti-viral activity for the 1600 μg dose and a trend for protection for the 160 μg dose under the conditions of the hamster model (<xref ref-type="fig" rid="F4">Figure 4b-g</xref>).</p>
<p id="P14">Histopathology results: Intranasal infection with SARS-CoV-2 induced epithelial inflammation and degeneration of the respiratory tract from the nasal turbinates, through the trachea to the bronchi/bronchioles of the lung. More specifically, the inflammation comprised a mixed inflammatory cell infiltrate of lymphocytes, macrophages, plasma, cells and granulocytes which was variably accompanied by epithelial degeneration, regeneration, disorganization, single cell necrosis and inflammatory exudates in the bronchial lumen and nasal cavity. In the lung of more severely affected animals the inflammation extended from the bronchial epithelium to adjacent alveolar interstitium, alveolar sacs and blood vessels (with or without perivascular edema); prominent Type II alveolar pneumocytes and variable hemorrhage were also variably present within the lesion. These findings were most severe in SARS-CoV-2 infected animals receiving the vehicle and the lowest dose of 16ug multivalent DARPin MR-DC. While there was some reduction in the severity of the lesion in infected animals given 160 ug, there was a significant improvement in animals treated with the highest dose of 1600 ug (<xref ref-type="fig" rid="F4">Figure 4b</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 9</xref>).</p>
<p id="P15">SARS-CoV-2 infection was accompanied by a reactive change in lymphoid organs consistent with immune activation. Activation of germinal centers was accompanied by increased cellularity of the white pulp in the spleen and increased cellularity of the medullary sinuses (macrophages and plasma cells) in the mandibular lymph node. Again, these findings were generally more apparent in infected animals receiving the vehicle, with a dose-related decrease in severity in MR-DC-treated groups, particularly in animals treated with the highest dose of 1600 ug (<xref ref-type="fig" rid="F4">Figure 4c</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 9</xref>). The pharmacokinetics for MR-DC, injected at 160 μg and 1600 μg per animal, was evaluated in an independent study in non-infected Syrian golden hamsters, proving systemic exposure for the duration of the in-life phase of this hamster PD model (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 10</xref>).</p>
</sec>
</sec>
<sec id="S7" sec-type="discussion">
<title>Discussion</title>
<p id="P16">Multiple strategies to combat the COVID-19 pandemic are urgently needed. Next to preventive vaccination approaches, monoclonal antibodies are showing therapeutic promise, based on highly potent virus inhibition and encouraging animal and clinical efficacy(<xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R29">29</xref>). However, due to the global need for COVID-19, manufacturing is expected to become a major bottleneck for vaccines and antibodies. A number of alternative molecules are being developed to complement and partially overcome this limitation of antibodies. Here we describe the generation of DARPin molecules - one prominent alternative to antibodies(<xref ref-type="bibr" rid="R30">30</xref>) amongst others(<xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R34">34</xref>) - that bind the SARS-CoV-2 spike protein. We tested a library of one trillion DARPin molecules and identified multiple DARPin molecules with different functionalities and binding specificities. By molecular linkage of individual DARPin molecules, we developed multivalent DARPin molecules with low picomolar neutralizing activity and demonstrated their protective efficacy against SARS-CoV-2 infection in a hamster model. In particular, reduced lung tissue damage and reduced virus replication in the lower and upper respiratory tract were observed, the latter also being important for reducing virus shedding and transmission. The most advanced of those multivalent DARPin molecules, MP0420 or ensovibep, is currently being studied in Phase 2.</p>
<p id="P17">The most potent neutralizing monovalent DARPin molecules were found to target the RBD, blocking the spike-ACE2 interaction necessary for infection. This finding is congruent with the identified epitopes of potent neutralizing antibodies obtained from COVID-19 patients(<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R35">35</xref>–<xref ref-type="bibr" rid="R39">39</xref>). Thus, the <italic>in vitro</italic> approach using DARPin molecules independently confirms that the ACE2 interaction site on the SARS-CoV-2 spike protein is one of the most vulnerable sites to block virus infection in cell culture. The single-chain binding domain nature of DARPin molecules facilitated the design of multiparatopic and multispecific DARPin molecules with greatly increased neutralization potencies. Virus neutralization capacity increased substantially when three DARPin molecules were linked - relative to the individual modules - likely due to both, increased avidity when binding to the trimeric spike proteins as well as multiple spike domains. A similar strategy with comparable outcome has been recently described for nanobodies. The observed <italic>in vitro</italic> neutralization capacity of the multivalent DARPin molecules in the low picomolar range is similar to or even outcompetes the neutralizing capacities of monoclonal antibodies. The protection against SARS-CoV-2 infections demonstrated in a hamster model at 1600 mg per animal (10 mg/kg) and the partial protection at 160 mg (1 mg/kg) is in the range reported for monoclonal antibodies(<xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R41">41</xref>).</p>
<p id="P18">The multivalent DARPin molecules are expected to retain potency even if the spike protein of SARS-CoV-2 should mutate considerably in the future, especially when multiple modes of action are addressed. Evaluation of the impact of a panel of reported mutations in the SARS-CoV-2 spike protein revealed no loss of neutralizing capacity of our lead candidates in a PsV NA and a set of emerging variants and spike protein mutations were recently reported elsewhere(<xref ref-type="bibr" rid="R42">42</xref>). Although it remains to be determined if additional mutations will impact the neutralization potencies of the multivalent DARPin molecules, we expect multivalent DARPin molecules to retain high potency in case the SARS-CoV-2 spike protein should mutate in the future.</p>
<p id="P19">DARPin molecules(<xref ref-type="bibr" rid="R30">30</xref>) have shown good promise for both ophthalmology and oncology patients. Within oncology, MP0250 is the DARPin molecule(<xref ref-type="bibr" rid="R7">7</xref>) with most systemic data available to date: MP0250 is a dual inhibitor of VEGF and HGF and is being developed for multiple myeloma in combination with small molecules. MP0250 shows a long systemic half-life of about 2 weeks in human, low immunogenicity potential, and has been given to individual patients for more than two years. All 42 patients in a phase I clinical trial maintained systemic exposure after repeated dosing while 2 patients, out of these 42 patients, showed elevated anti-drug antibodies which did not affect MP0250 exposure. Here, we demonstrate prophylactic protection from SARS-CoV-2 infection by a multivalent DARPin molecule in a hamster model. Reported systemic exposures, achieved with human serum albumin binding DARPin molecules, appear comparable to the half-lives reported for monoclonal antibodies. Due to the lack of an immune stimulating Fc-fragment, we envision no generation of antibody dependent enhancement (ADE) effects, a potential side-effect of monoclonal antibodies in patients with inflamed lungs(<xref ref-type="bibr" rid="R43">43</xref>–<xref ref-type="bibr" rid="R46">46</xref>). This hypothetical differentiation, when compared to monoclonal antibody treatments including immune stimulating Fc-fragments, is currently under clinical investigation and remains to be verified.</p>
<p id="P20">Generally, DARPin molecules demonstrate excellent temperature stability, which might enable alternative routes of administration, such as inhalation described for other highly stable protein scaffolds(<xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R48">48</xref>). The simple molecular architecture of multivalent DARPin molecules allows manufacturing in bacterial expression systems at very high yields which leads to cost-effective and scalable production of antiviral biologicals at industrial quantities (<xref ref-type="supplementary-material" rid="SD1">supplementary table 5</xref>). Consequently, global access to this novel class of therapeutics may be highly additive to monoclonal antibody approaches and thus contribute to overcoming the COVID-19 pandemic(<xref ref-type="bibr" rid="R49">49</xref>). We anticipate that the presented workflow for DARPin development can be applied for any future emerging (corona)virus. We have proven that high-affinity binding and potently neutralizing DARPin molecules can be developed in a matter of weeks, without the requirement of immunization of animals or access to patient materials. Such fast track development strategies of picomolar inhibitors are critical to raise preparedness level towards novel pandemic viruses.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Material</label>
<media xlink:href="EMS94260-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66947" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S8">
<title>Acknowledgements</title>
<p>We would particularly like to thank those colleagues at Molecular Partners who are not included in the author list and are currently advancing the program through the clinic. Additionally, we would like to thank William Lee, former board member of Molecular Partners - and the Virology group at Gilead Sciences for their helpful input. The authors also thank Dr. Gert Zimmer for the gift of the recombinant VSV (Institute of Virology and Immunology (IVI), CH-3147 Mittelhäusern, Switzerland, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, CH-3012 Bern, Switzerland). The expression plasmid for the SARS-CoV-2 spike protein was kindly provided by Dr. Giulia Torriani and Dr. Isabella Eckerle (Department of Medicine, University of Geneva, Switzerland). SR &amp; JM were supported by Swiss Federal Office for Civil Protection (Grants Nr. 353008564/Stm, 353008218/Stm, and 353008560/Stm to Olivier Engler and Stefan Kunz).</p>
<p>We would like to thank for the supply of the two 2019-nCoV strains: i) 2019-nCoV/IDF0372/2020 provided by the National Reference Centre for Respiratory Viruses hosted by Institut Pasteur (Paris, France) and headed by Dr. Sylvie van der Werf as well as the human sample from which strain 2019-nCoV/IDF0372/2020 was isolated, provided by Dr. X. Lescure and Pr. Y. Yazdanpanah from the Bichat Hospital.</p>
<p>D.L.H. is funded from by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (No 842333) and holds an EMBO non-stipendiary long-term Fellowship (ALTF 1172-2018). Cryo-EM data processing was carried out on the Dutch national e-infrastructure with the support of SURF Cooperative.</p>
<sec id="S9">
<title>Funding</title>
<p>All studies were funded by Molecular Partners AG, Switzerland.</p>
</sec>
</ack>
<sec id="S10" sec-type="data-availability">
<title>Data availability</title>
<p id="P21">The EM density maps for the SARS-CoV-2 a with monovalent DARPin #3 (state 1 and state 2), and monovalent DARPin #9 have been deposited to the Electron Microscopy Data Bank under the accession codes EMD-11953, EMD-11954 and EMD-11956, respectively. The monovalent DARPin and multivalent DARPin sequences, and pseudo-atomic models derived from molecular docking experiments, are available (by contacting the corresponding author) for research purposes only under an MTA, which allows the use of the data for non-commercial purposes but not their disclosure to third parties.</p>
</sec>
<fn-group>
<fn id="FN3" fn-type="con">
<p id="P22">
<bold>Author contributions</bold>
</p>
<p id="P23">M.W., S.R., D.L.H., V.C., C.R., S.F., A.Z., N.V., K.M.D., C.Z., M.A.H., L.d.W., K.J.S., F.J.M.v.K., O.E. , B.-J. B., M.T.S.; P.A.: conceptualized and designed experiments; M.W., S.R., D.L.H., A.S., D.V., M.P., T.H., A.N., A.C., P.S., M.M., M.H., M.F., Y.K., I.S., C.I., T.L., S.M., C.H., D.S., A.B., A.L., T.V., G.S., K.P., M.S., J.M., S.Ry., S.T., H.L., C.W., W.L., I.D.: performed laboratory experiments; D.L.H., C.R, F.R.: performed computational work; M.W., S.R., D.L.H., H.K.B., S.L., S.F., F.J.M.v.K., O.E., B.-J. B., M.T.S., P.A. drafted the manuscript. S.L., D.S., M.T.S., P.A. acquired funding. All authors reviewed the manuscript.</p>
</fn>
<fn id="FN4" fn-type="conflict">
<p id="P24">
<bold>Competing interests:</bold> Molecular Partners authors own performance share units and/or stock of the company. HKB owns stock of the company.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>270</fpage>
<lpage>273</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiang</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>The effect of large-scale anti-contagion policies on the COVID-19 pandemic</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>262</fpage>
<lpage>267</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flaxman</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>257</fpage>
<lpage>261</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guy</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>DiPaola</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Romanelli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dutch</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Rapid repurposing of drugs for COVID-19</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>829</fpage>
<lpage>830</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ledford</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>333</fpage>
<lpage>334</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Binz</surname>
<given-names>HK</given-names>
</name>
<etal/>
</person-group>
<article-title>High-affinity binders selected from designed ankyrin repeat protein libraries</article-title>
<source>Nat Biotechnol</source>
<year>2004</year>
<volume>22</volume>
<fpage>575</fpage>
<lpage>582</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baird</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>
<article-title>First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors</article-title>
<source>J Clin Oncol</source>
<year>2021</year>
<volume>39</volume>
<fpage>145</fpage>
<lpage>154</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shang</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>581</volume>
<fpage>221</fpage>
<lpage>224</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Structural insights into coronavirus entry</article-title>
<source>Adv Virus Res</source>
<year>2019</year>
<volume>105</volume>
<fpage>93</fpage>
<lpage>116</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letko</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Munster</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title>
<source>Nat Microbiol</source>
<year>2020</year>
<volume>5</volume>
<fpage>562</fpage>
<lpage>569</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>271</fpage>
<lpage>280</lpage>
<elocation-id>e278</elocation-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer</article-title>
<source>Nature</source>
<year>2016</year>
<volume>531</volume>
<fpage>114</fpage>
<lpage>117</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>281</fpage>
<lpage>292</lpage>
<elocation-id>e286</elocation-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2017</year>
<volume>114</volume>
<fpage>11157</fpage>
<lpage>11162</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zahnd</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Amstutz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pluckthun</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target</article-title>
<source>Nat Methods</source>
<year>2007</year>
<volume>4</volume>
<fpage>269</fpage>
<lpage>279</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jermutus</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Weber-Bornhauser</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bosshard</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Pluckthun</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>1998</year>
<volume>95</volume>
<fpage>14130</fpage>
<lpage>14135</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Binz</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Stumpp</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Forrer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Amstutz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pluckthun</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins</article-title>
<source>J Mol Biol</source>
<year>2003</year>
<volume>332</volume>
<fpage>489</fpage>
<lpage>503</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion</article-title>
<source>Cell</source>
<year>2019</year>
<volume>176</volume>
<fpage>1026</fpage>
<lpage>1039</lpage>
<elocation-id>e1015</elocation-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niesen</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Berglund</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vedadi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</article-title>
<source>Nat Protoc</source>
<year>2007</year>
<volume>2</volume>
<fpage>2212</fpage>
<lpage>2221</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1010</fpage>
<lpage>1014</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<fpage>290</fpage>
<lpage>295</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<etal/>
</person-group>
<article-title>Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>828</fpage>
<lpage>842</lpage>
<elocation-id>e816</elocation-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>
<source>Science</source>
<year>2020</year>
<volume>367</volume>
<fpage>1260</fpage>
<lpage>1263</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrobel</surname>
<given-names>AG</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects</article-title>
<source>Nat Struct Mol Biol</source>
<year>2020</year>
<volume>27</volume>
<fpage>763</fpage>
<lpage>767</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Distinct conformational states of SARS-CoV-2 spike protein</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1586</fpage>
<lpage>1592</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>650</fpage>
<lpage>655</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>1110</fpage>
<lpage>1115</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>384</volume>
<fpage>229</fpage>
<lpage>237</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>BE</given-names>
</name>
<etal/>
</person-group>
<article-title>LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stumpp</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Binz</surname>
<given-names>HK</given-names>
</name>
</person-group>
<article-title>Beyond Antibodies: The DARPin((R)) Drug Platform</article-title>
<source>BioDrugs</source>
<year>2020</year>
<volume>34</volume>
<fpage>423</fpage>
<lpage>433</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoof</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>1473</fpage>
<lpage>1479</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>De novo design of picomolar SARS-CoV-2 miniprotein inhibitors</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>426</fpage>
<lpage>431</lpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linsky</surname>
<given-names>TW</given-names>
</name>
<etal/>
</person-group>
<article-title>De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>1208</fpage>
<lpage>1214</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walter</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Hutter</surname>
<given-names>CAJ</given-names>
</name>
<name>
<surname>Garaeva</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Highly potent bispecific sybodies neutralize SARS-CoV-2</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brouwer</surname>
<given-names>PJM</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>643</fpage>
<lpage>650</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>450</fpage>
<lpage>456</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname>
<given-names>TF</given-names>
</name>
<etal/>
</person-group>
<article-title>Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>956</fpage>
<lpage>963</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>120</fpage>
<lpage>124</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Potently neutralizing and protective human antibodies against SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>443</fpage>
<lpage>449</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreye</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>1058</fpage>
<lpage>1069</lpage>
<elocation-id>e1019</elocation-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haagmans</surname>
<given-names>BL</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothenberger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Walser</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Multi-specific DARPin® therapeutics demonstrate very high potency against mutated SARS-CoV-2 variants in vitro</article-title>
<source>bioRxiv</source>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title>
<source>JCI Insight</source>
<year>2019</year>
<volume>4</volume>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arvin</surname>
<given-names>AM</given-names>
</name>
<etal/>
</person-group>
<article-title>A perspective on potential antibody-dependent enhancement of SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>353</fpage>
<lpage>363</lpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Simeonov</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2</article-title>
<source>Trends Pharmacol Sci</source>
<year>2020</year>
<volume>41</volume>
<fpage>815</fpage>
<lpage>829</lpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zohar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Alter</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Dissecting antibody-mediated protection against SARS-CoV-2</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<fpage>392</fpage>
<lpage>394</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nambulli</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthews</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Ee</surname>
<given-names>PLR</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Developing inhaled protein therapeutics for lung diseases</article-title>
<source>Molecular Biomedicine</source>
<year>2020</year>
<volume>1</volume>
<fpage>1</fpage>
<lpage>14</lpage>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ledford</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The race to make COVID antibody therapies cheaper and more potent</article-title>
<source>Nature</source>
<year>2020</year>
<volume>587</volume>
<fpage>18</fpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Binz</surname>
<given-names>HK</given-names>
</name>
<etal/>
</person-group>
<article-title>Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin(R) drug candidate</article-title>
<source>MAbs</source>
<year>2017</year>
<volume>9</volume>
<fpage>1262</fpage>
<lpage>1269</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torriani</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>Macropinocytosis contributes to hantavirus entry into human airway epithelial cells</article-title>
<source>Virology</source>
<year>2019</year>
<volume>531</volume>
<fpage>57</fpage>
<lpage>68</lpage>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>2251</fpage>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zivanov</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>New tools for automated high-resolution cryo-EM structure determination in RELION-3</article-title>
<source>Elife</source>
<year>2018</year>
<volume>7</volume>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>SQ</given-names>
</name>
<etal/>
</person-group>
<article-title>MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy</article-title>
<source>Nat Methods</source>
<year>2017</year>
<volume>14</volume>
<fpage>331</fpage>
<lpage>332</lpage>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Gctf: Real-time CTF determination and correction</article-title>
<source>J Struct Biol</source>
<year>2016</year>
<volume>193</volume>
<fpage>1</fpage>
<lpage>12</lpage>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</name>
<etal/>
</person-group>
<article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title>
<source>J Comput Chem</source>
<year>2004</year>
<volume>25</volume>
<fpage>1605</fpage>
<lpage>1612</lpage>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Garcia</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>DeepEMhancer: a deep learning solution for cryo-EM volume post-processing</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Cianfrocco</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>R</given-names>
</name>
</person-group>
<conf-name>paper presented at the The Practice and Experience in Advanced Research Computing</conf-name>
<conf-loc>New Orleans, LA</conf-loc>
<year>2017</year>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leaver-Fay</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules</article-title>
<source>Methods Enzymol</source>
<year>2011</year>
<volume>487</volume>
<fpage>545</fpage>
<lpage>574</lpage>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>PS</given-names>
</name>
<etal/>
</person-group>
<article-title>RosettaRemodel: a generalized framework for flexible backbone protein design</article-title>
<source>PLoS One</source>
<year>2011</year>
<volume>6</volume>
<elocation-id>e24109</elocation-id>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nivon</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Moretti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A Pareto-optimal refinement method for protein design scaffolds</article-title>
<source>PLoS One</source>
<year>2013</year>
<volume>8</volume>
<elocation-id>e59004</elocation-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurdiss</surname>
<given-names>DL</given-names>
</name>
<etal/>
</person-group>
<article-title>Cryo-EM structure of coronavirus-HKU1 haemagglutinin esterase reveals architectural changes arising from prolonged circulation in humans</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>4646</elocation-id>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudhury</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Benchmarking and analysis of protein docking performance in Rosetta v3.2</article-title>
<source>PLoS One</source>
<year>2011</year>
<volume>6</volume>
<elocation-id>e22477</elocation-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallace</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Laskowski</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions</article-title>
<source>Protein Eng</source>
<year>1995</year>
<volume>8</volume>
<fpage>127</fpage>
<lpage>134</lpage>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goddard</surname>
<given-names>TD</given-names>
</name>
<etal/>
</person-group>
<article-title>UCSF ChimeraX: Meeting modern challenges in visualization and analysis</article-title>
<source>Protein Sci</source>
<year>2018</year>
<volume>27</volume>
<fpage>14</fpage>
<lpage>25</lpage>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morin</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Collaboration gets the most out of software</article-title>
<source>Elife</source>
<year>2013</year>
<volume>2</volume>
<elocation-id>e01456</elocation-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laskowski</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Swindells</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>LigPlot+: multiple ligand-protein interaction diagrams for drug discovery</article-title>
<source>J Chem Inf Model</source>
<year>2011</year>
<volume>51</volume>
<fpage>2778</fpage>
<lpage>2786</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Process overview for the generation of anti-SARS-CoV-2 multivalent DARPin molecules.</title>
<p>Upper panel, generation and evaluation of monovalent DARPin molecules. Lower panel, assembly and deep-characterization of multivalent DARPin molecules.</p>
</caption>
<graphic xlink:href="EMS94260-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Architecture, diversity and <italic>in vitro</italic> potency of two multivalent DARPin molecules.</title>
<p>a) Ribbon structure and semi-transparent surface representation of a monovalent DARPin molecule. The designed ankyrin repeats are colored alternatingly in white and blue for the five repeats. The randomized residues present in the rigid target binding surface are colored orange. b) Schematic overview of the MR-DC and MM-DC constructs. Protein linkers are depicted as gray dashed lines and the half-life extending human serum albumin binding monovalent DARPin (H) is colored yellow. c) Sequence family tree illustrating the sequence diversity amongst the 11 monovalent DARPin molecules chosen for the generation of multivalent DARPin molecules. Surface representations of five Monovalent DARPin molecules binding to the RBD, NTD or S2 are shown, with the amino acid residues in the binding surface colored according to their biophysical characteristics as indicated. d, e) DARPin-respectively antibody-mediated neutralization of infection of luciferase-encoding VSV particles pseudotyped with the SARS-CoV-2 spike protein. Pseudotype VSV particles pre-incubated with monovalent DARPin molecules (d), multivalent DARPin molecules (MM-DC and MR-DC) or control antibodies (e) at the indicated concentrations were used to infect VeroE6 cells. Luciferase activities in cell lysates were determined at 24 h post transduction to calculate infection (%) relative to mock-treated virus controls. The average ± SD from two independent experiments performed in sextuplicate is shown. f) Multivalent DARPin-mediated cell protection of SARS-CoV-2 infection. SARS-CoV-2 pre-incubated with multivalent DARPin molecules MM-DC or MR-DC, or with isotype negative control (isotype NC) at the indicated concentrations were used to infect VeroE6 cells. Cell viability was determined using the CellTiter-Glo luminescent cell viability assay and represented as relative (%) to mock infected cells. Half-maximal inhibitory concentration values (IC<sub>50</sub>) of DARPin molecules and antibodies are indicated in the lower panel tables (d-f).</p>
</caption>
<graphic xlink:href="EMS94260-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Cryo-EM analysis of monovalent DARPin molecules.</title>
<p>A) Cryo-EM density for the SARS-CoV-2 spike ectodomain in complex with the RBD targeting monovalent DARPin #3, shown as two orthogonal views. The DARPin density is colored magenta and the three spike protomers are colored light blue, grey and pink. B) Zoomed in view of a single DARPin #3-bound RBD with the cryo-EM density shown semi-transparent. The atomic coordinates for the fitted fully open spike (PDB ID: 6XCN) and the DARPin homology model are overlaid. The atomic coordinates for residues 1-84 of the RBD bound ACE2 (PDB ID: 6M0J), colored green, is superimposed. C) Proposed model of three covalently linked RBD-targeting monovalent DARPin molecules shown in a rainbow color scheme from the N terminus (blue) to the C terminus (red). D) Cryo-EM density for the SARS-CoV-2 spike ectodomain in complex with the NTD targeting monovalent DARPin #9, shown as two orthogonal views. The mono-DARPin #9 density is colored blue and the three spike protomers are colored light blue, grey and pink. E) Zoomed in view of the DARPin molecule #9 bound to the NTD with the cryo-EM density shown semi-transparent. The atomic coordinates for the fitted fully closed spike (PDB ID: 6ZGE) and the DARPin homology model are overlaid and colored grey and blue, respectively. The N3 and N5 loops are labelled and glycans are shown in stick representation and colored orange. F) Proposed model of the covalently linked NTD and RBD targeting monovalent DARPin molecules, shown in a rainbow color scheme from the N terminus (blue) to the C terminus (red).</p>
</caption>
<graphic xlink:href="EMS94260-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>In-vivo efficacy of MR-DC in treating SARS-CoV-2 infection in a preventive Syrian golden hamster model.</title>
<p>a) study design: six animals were used per dose group. Generally high variations were observed in control and treatment groups. At Day-2, body weight (W) was measured, blood (B) was taken, and the first throat swab (Sw) performed. Animals were euthanized on Day 4 and tissue (Tis) were taken and gross pathology (Gp) was performed. (b) Histopathological changes in the respiratory tract (lung - blue bars, trachea and nasal turbinates – grey bars). (c) Histopathological changes in lymphoid organs (spleen - green bars, mandibular lymph nodes - yellow bars). A trend to dose-dependent reduction of body-weight loss at day 4 (d), virus titers post challenge for throat swabs (e), nasal turbinate (f) and significant reduction of viral loads in the lung at 1600 μg (10 mg/kg), with two animals below detection limit, as well as a trend to dose-dependent reduction of viral loads at 160 μg (1 mg/kg) (g). Statistically significant differences between Placebo and 1600 μg group: *T-test; P value = 0.0183 / **T-test; P value = 0.0031.</p>
</caption>
<graphic xlink:href="EMS94260-f004"/>
</fig>
</floats-group>
</article>
